These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29986086)

  • 1. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
    López-Cortés LF; Trujillo-Rodríguez M; Báez-Palomo A; Benmarzouk-Hidalgo OJ; Dominguez-Molina B; Milanés-Guisado Y; Espinosa N; Viciana P; Gutiérrez-Valencia A
    J Infect Dis; 2018 Jul; 218(4):624-632. PubMed ID: 29986086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
    BenMarzouk-Hidalgo OJ; Torres-Cornejo A; Gutierrez-Valencia A; Ruiz-Valderas R; Viciana P; López-Cortés LF
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):6-11. PubMed ID: 26414169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
    d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
    J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis.
    Girón-Ortega JA; Márquez-Coello M; Gutiérrez-Saborido D; Arizcorreta A; Cuesta-Sancho S; Girón-González JA
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1863-1871. PubMed ID: 33822285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    Griesbeck M; Valantin MA; Lacombe K; Samri-Hassimi A; Bottero J; Blanc C; Sbihi Z; Zoorob R; Katlama C; Guiguet M; Altfeld M; Autran B;
    AIDS; 2017 Jun; 31(9):1223-1234. PubMed ID: 28492391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
    Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients.
    Medrano LM; Garcia-Broncano P; Berenguer J; González-García J; Jiménez-Sousa MÁ; Guardiola JM; Crespo M; Quereda C; Sanz J; Canorea I; Carrero A; Hontañón V; Muñoz-Fernández MÁ; Resino S;
    AIDS; 2018 Jun; 32(9):1095-1105. PubMed ID: 29438197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy.
    Gutiérrez-Saborido D; Gutiérrez-Valencia A; González Domenech CM; López Ruz MÁ; Raffo Márquez M; Omar M; Girón-González JA;
    Ann Hematol; 2019 Aug; 98(8):1953-1959. PubMed ID: 31025161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
    Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
    Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.
    Casado JL; Abad-Fernández M; Moreno S; Pérez-Elías MJ; Moreno A; Bernardino JI; Vallejo A
    HIV Med; 2015 Apr; 16(4):240-8. PubMed ID: 25604328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study.
    Garcia-Broncano P; Medrano LM; Berenguer J; Brochado-Kith O; González-García J; Jiménez-Sousa MÁ; Quereda C; Sanz J; Téllez MJ; Díaz L; JIménez JL; Resino S;
    J Infect; 2020 Jan; 80(1):99-110. PubMed ID: 31585189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
    Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
    Al-Harthi L; Voris J; Du W; Wright D; Nowicki M; Frederick T; Landay A; Kovacs A
    J Infect Dis; 2006 May; 193(9):1202-10. PubMed ID: 16586355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of CD4⁺ T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients.
    Hodowanec AC; Brady KE; Gao W; Kincaid SL; Plants J; Bahk M; Landay AL; Huhn GD
    J Acquir Immune Defic Syndr; 2013 Nov; 64(3):232-40. PubMed ID: 24131865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.
    Kostadinova L; Shive CL; Judge C; Zebrowski E; Compan A; Rife K; Hirsch A; Falck-Ytter Y; Schlatzer DM; Li X; Chance MR; Rodriguez B; Popkin DL; Anthony DD
    J Infect Dis; 2016 Nov; 214(9):1438-1448. PubMed ID: 27540113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
    Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
    Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection.
    Shmagel KV; Saidakova EV; Shmagel NG; Korolevskaya LB; Chereshnev VA; Robinson J; Grivel JC; Douek DC; Margolis L; Anthony DD; Lederman MM
    HIV Med; 2016 Sep; 17(8):581-9. PubMed ID: 27187749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals.
    Abad-Fernández M; Vallejo A; Hernández-Novoa B; Díaz L; Gutiérrez C; Madrid N; Muñoz MA; Moreno S
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):149-53. PubMed ID: 24047967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Milazzo L; Foschi A; Mazzali C; Viola A; Ridolfo A; Galli M; Antinori S
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):989-93. PubMed ID: 22220723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.